Corbus Pharmaceuticals Holding (NASDAQ:CRBP) — Market Cap & Net Worth
Market Cap & Net Worth: Corbus Pharmaceuticals Holding (CRBP)
Corbus Pharmaceuticals Holding (NASDAQ:CRBP) has a market capitalization of $140.42 Million ($140.42 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17994 globally and #4226 in its home market, demonstrating a -18.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corbus Pharmaceuticals Holding's stock price $7.26 by its total outstanding shares 19341293 (19.34 Million). Also see Corbus Pharmaceuticals Holding assets under control for a full breakdown of the balance sheet.
Corbus Pharmaceuticals Holding Market Cap History: 2015 to 2026
Corbus Pharmaceuticals Holding's market capitalization history from 2015 to 2026. Data shows change from $957.39 Million to $140.42 Million (-16.61% CAGR). Also see Corbus Pharmaceuticals Holding cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Corbus Pharmaceuticals Holding is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #498 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1750 of 3165 |
Weight: Corbus Pharmaceuticals Holding's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corbus Pharmaceuticals Holding Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corbus Pharmaceuticals Holding's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Corbus Pharmaceuticals Holding (CRBP) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
405.18x
Corbus Pharmaceuticals Holding's market cap is 405.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.90 Billion | $1.91 Million | -$20.00 Million | 2565.11x | N/A |
| 2017 | $4.12 Billion | $2.44 Million | -$32.42 Million | 1688.26x | N/A |
| 2018 | $3.39 Billion | $4.82 Million | -$55.67 Million | 702.70x | N/A |
| 2019 | $3.17 Billion | $36.14 Million | -$71.45 Million | 87.65x | N/A |
| 2020 | $725.30 Million | $3.94 Million | -$111.27 Million | 184.22x | N/A |
| 2021 | $357.25 Million | $881.71K | -$45.55 Million | 405.18x | N/A |
Competitor Companies of CRBP by Market Capitalization
Companies near Corbus Pharmaceuticals Holding in the global market cap rankings as of September 18, 2026. Review Corbus Pharmaceuticals Holding tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Corbus Pharmaceuticals Holding by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Corbus Pharmaceuticals Holding Historical Marketcap From 2015 to 2026
Between 2015 and today, Corbus Pharmaceuticals Holding's market cap moved from $957.39 Million to $ 140.42 Million, with a yearly change of -16.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $140.42 Million | -10.81% |
| 2025 | $157.44 Million | -31.02% |
| 2024 | $228.23 Million | +95.36% |
| 2023 | $116.82 Million | +82.20% |
| 2022 | $64.12 Million | -82.05% |
| 2021 | $357.25 Million | -50.74% |
| 2020 | $725.30 Million | -77.11% |
| 2019 | $3.17 Billion | -6.51% |
| 2018 | $3.39 Billion | -17.75% |
| 2017 | $4.12 Billion | -15.98% |
| 2016 | $4.90 Billion | +412.12% |
| 2015 | $957.39 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Corbus Pharmaceuticals Holding was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $140.42 Million USD |
| MoneyControl | $140.42 Million USD |
| MarketWatch | $140.42 Million USD |
| marketcap.company | $140.42 Million USD |
| Reuters | $140.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more